Save up -80% on Linagliptin
|Note: this is a drug discount program, not an insurance plan.|
|RX BIN: 015558||RX PCN: HT||Group ID: DDN6600||Card Holder ID: DDN6600|
|Pharmacists and Patients support.|
2019 Price of Tradjenta
|$377.77||30 tablets/5 mg|
|price without discount in nearest pharmacy. Price may vary.|
We offer free Tradjenta coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your manufacturer copay card in most local pharmacies to get a discount on Linagliptin every time. What are you waiting for? Claim your prescription drug card now!
Get your Prescription
It’s safe and free
Buy drugs in pharmacy
Save money each time
Linagliptin volume of distribution
Distribution The mean apparent volume of distribution at steady state following a single intravenous dose of linagliptin 5 mg to healthy subjects is approximately 1110 L, indicating that linagliptin extensively distributes to the tissues.
Discount Cards 16,000+
Clients Benefit 29%
Total savings $4,735,080
What is Linagliptin
Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes[Wikipedia]. Two pharmacological characteristics that sets linagliptin apart from other DPP-4 inhibitors is that it has a non-linear pharmacokinetic profile and is not primarily eliminated by the renal system. FDA approved on May 2, 2011.
Linagliptin mechanism of action
Linagliptin is a competitive and reversible dipeptidyl peptidase (DPP)-4 enzyme inhibitor that slows the breakdown of insulinotropic hormone glucagon-like peptide (GLP)-1 for better glycemic control in diabetes patients. GLP and glucose-dependent insulinotropic polypeptide (GIP) are incretin hormones that increase the production and release of insulin from pancreatic beta cells and decrease the release of glucagon from pancreatic alpha cells. This results in a overall decrease in glucose production in the liver and increase an of insulin in a glucose-dependent manner.
Dosage forms of Linagliptin
|Tablet, film coated||oral|
|Tablet, film coated, extended release||oral|
(R)-8-(3-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methylquinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione BI 1356
Boehringer Ingelheim Pharmaceuticals, Inc.
Humans and other mammals
Indication of Linagliptin
Linagliptin is used for the management of type 2 diabetes mellitus.
Toxicity of Linagliptin
The cause of possible liver injury during linagliptin therapy is not known. The drug is mostly metabolized by the liver, largely by the cytochrome P450 system (CYP 3A4), and a toxic or immunogenic intermediate of metabolism may be produced that could cause liver injury.
RX24 Drugs Disclaimer: consult your healthcare provider before buying a Linagliptin on prescription or using an RX manufacturer savings coupon. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.
Get lower price on Linagliptin now!
What is Trajenta?
Trajenta is a relatively new class of antidiabetic drugs. DPP-4 inhibitors with an oral route of administration are successfully used to control type 2 diabetes; a large evidence base of its effectiveness has been accumulated. The active ingredient of the drug is linagliptin. Diabetics with kidney pathologies are especially appreciated for its benefits, since the drug does not put an additional burden on them.
The manufacturers, BOEHRINGER INGELHEIM PHARMA (Germany) and BOEHRINGER INGELHEIM ROXANE (USA), produce medicine in the form of convex round tablets of red color. On one side is the engraved symbol of the manufacturer, which protects the drug from counterfeit, on the other – the label “D5”. Each of them contains 5 mg of the active ingredient linagliptin and various fillers such as starch, dye, hypromellose, magnesium stearate, copovidone, macrogol.
The mechanism of action Trajenta is similar to the principles of operation of other analogues – Januvia, Galvus, Onglyza. GUI and GLP-1 are produced at the time of entry into the body of nutrients. The effectiveness of the drug is not associated with the stimulation of their production, the drug simply increases the duration of their exposure. Due to such characteristics, Trajenta, like other incontinomimetics, does not provoke the development of hypoglycemia and this is their significant advantage over other classes of hypoglycemic drugs.